Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

March 31, 2008

Conditions
Graft-Versus-Host Disease
Interventions
DRUG

Infliximab

"A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"

Trial Locations (1)

43210

Ohio State University, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00201799 - Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter